Cellectar BioSciences, Inc. (CLRB)

NASDAQ: CLRB · IEX Real-Time Price · USD
1.85
-0.02 (-1.07%)
At close: Dec 5, 2022 4:00 PM
1.78
-0.07 (-3.78%)
After-hours: Dec 5, 2022 4:31 PM EST
-1.07%
Market Cap 17.55M
Revenue (ttm) n/a
Net Income (ttm) -27.30M
Shares Out 6.11M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,076
Open 1.89
Previous Close 1.87
Day's Range 1.81 - 1.91
52-Week Range 1.75 - 7.9
Beta 1.19
Analysts Buy
Price Target 12.85 (+594.6%)
Earnings Date Nov 14, 2022

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company... [Read more]

Industry Biotechnology
Founded 2002
CEO James Caruso
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CLRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is 12.85, which is an increase of 594.59% from the latest price.

Price Target
$12.85
(594.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

5 days ago - GlobeNewsWire

Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the ...

Preclinical data demonstrate ability to deliver targeted alpha-emitting isotopes to malignant cells and therapeutic efficacy Preclinical data demonstrate ability to deliver targeted alpha-emitting isoto...

2 weeks ago - GlobeNewsWire

Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute

Secures license to the patents at issue in the lawsuit Secures license to the patents at issue in the lawsuit

2 weeks ago - GlobeNewsWire

Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...

1 month ago - GlobeNewsWire

Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximat...

FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

1 month ago - GlobeNewsWire

Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 M...

FLORHAM PARK, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

1 month ago - GlobeNewsWire

Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of t...

2 months ago - GlobeNewsWire

Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in ...

Initial data show ORR of 50% in Quad-Class Refractory Multiple Myeloma Patients Who Have Failed anti-BCMA Immunotherapy with Median of Nine Lines of Prior Therapy Initial data show ORR of 50% in Quad-Cl...

2 months ago - GlobeNewsWire

Cellectar Reports Financial Results for Second Quarter 2022

FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...

4 months ago - GlobeNewsWire

Cellectar Announces Stock Consolidation

FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...

4 months ago - GlobeNewsWire

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializati...

6 months ago - GlobeNewsWire

Cellectar Biosciences Announces Key Commercial Team Appointments

Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances

7 months ago - GlobeNewsWire

Here's Why Cellectar Biosciences Shares Are Rising

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earn...

8 months ago - Benzinga

Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., March 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializa...

8 months ago - GlobeNewsWire

Cellectar to Participate at Upcoming Banking Conferences

FLORHAM PARK, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercializ...

8 months ago - GlobeNewsWire

Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference

FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

11 months ago - GlobeNewsWire

Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting a...

Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma

11 months ago - GlobeNewsWire

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Ex...

FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

11 months ago - GlobeNewsWire

Cellectar's Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted dru...

1 year ago - GlobeNewsWire

Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

Successful track record of developing and advancing oncology clinical programs through regulatory approval Successful track record of developing and advancing oncology clinical programs through regulato...

1 year ago - GlobeNewsWire

Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed o...

1 year ago - Benzinga

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for t...

1 year ago - GlobeNewsWire

Cellectar Receives $2M NIH Grant For Rare Lymphoma Study

Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the Na...

1 year ago - Benzinga

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's ...

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...

1 year ago - GlobeNewsWire